Skip to main content
. 2019 May 29;10(6):414. doi: 10.3390/genes10060414

Figure 5.

Figure 5

(A,B) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the gender groups. (C,D) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the age groups. (E,F) ROC analyses of sensitivity and specificity for the four-pseudogene signature in predicting the OS of patients for 3, 5, and 8 years in the metastatic groups.